Payment overview · 2025
General Payments
$1,251.95
63 reported records · 12 companies
Healthcare provider profile · identity verified
Malabika Dey, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WORCESTER, MA · NPI 1629000153
Verified facts
What the public records show
CMS Open Payments records show Malabika Dey, M.D. received $1,251.95 in general payments during 2025 across 63 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Rexulti.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $296.55 | 23.7% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $264.11 | 21.1% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $233.71 | 18.7% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $162.75 | 13.0% | 18 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $71.13 | 5.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.17 | 4.7% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.74 | 4.0% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $43.18 | 3.5% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.59 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.10 | 1.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.68 | 1.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.24 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,251.95 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $281.32 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $255.30 | 14 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $236.27 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $162.75 | 18 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $92.85 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $71.13 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $69.90 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $59.17 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $59.17 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $49.74 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $43.18 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $27.84 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 77 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 390 | 114 |
| Lisinopril | Lisinopril | 324 | 98 |
| Omeprazole | Omeprazole | 321 | 94 |
| Simvastatin | Simvastatin | 298 | 76 |
| Gabapentin | Gabapentin | 296 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 244 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 221 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 215 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 205 | 60 |
| Tramadol Hcl | Tramadol Hcl | 200 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 52 |
| Montelukast Sodium | Montelukast Sodium | 163 | 49 |
| Ibuprofen | Ibuprofen | 140 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 134 | 39 |
| Trazodone Hcl | Trazodone Hcl | 124 | 35 |
| Metformin Hcl | Metformin Hcl | 114 | 37 |
| Spironolactone | Spironolactone | 106 | 35 |
| Clonidine Hcl | Clonidine Hcl | 101 | 24 |
| Metformin Hcl Er | Metformin Hcl | 101 | 28 |
| Methylprednisolone | Methylprednisolone | 96 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 19 |
| Losartan Potassium | Losartan Potassium | 94 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 91 | 25 |
| Irbesartan | Irbesartan | 90 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 86 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 13 |
| Azithromycin | Azithromycin | 78 | 53 |
| Eliquis | Apixaban | 77 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 27 |
| Atenolol | Atenolol | 76 | 19 |
| Sertraline Hcl | Sertraline Hcl | 75 | 26 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 74 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 70 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 22 |
| Chlorthalidone | Chlorthalidone | 66 | 25 |
| Famotidine | Famotidine | 65 | 15 |
| Trulicity | Dulaglutide | 63 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 21 |
| Mirtazapine | Mirtazapine | 62 | 17 |
| Baclofen | Baclofen | 59 | 12 |
| Carvedilol | Carvedilol | 57 | 16 |
| Potassium Chloride | Potassium Chloride | 57 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 55 | suppressed |
| Furosemide | Furosemide | 52 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 12 |
| Meclizine Hcl | Meclizine Hcl | 48 | 15 |
| Bupropion Xl | Bupropion Hcl | 47 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 17 |
| Meloxicam | Meloxicam | 47 | 13 |
| Levofloxacin | Levofloxacin | 44 | 26 |
| Methadone Hcl | Methadone Hcl | 43 | suppressed |
| Sulfasalazine | Sulfasalazine | 42 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 41 | 23 |
| Ketoconazole | Ketoconazole | 41 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Lidocaine | Lidocaine | 36 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Pregabalin | Pregabalin | 34 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 24 |
| Carbamazepine Er | Carbamazepine | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 12 |
| Fentanyl | Fentanyl | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 29 | 15 |
| Allopurinol | Allopurinol | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Prednisone | Prednisone | 28 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 26 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 12 |
| Glipizide | Glipizide | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 21 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 11 |
| Fluconazole | Fluconazole | 16 | 13 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,251.95 · 63 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CREON, ELIQUIS, GEMTESA, IBSRELA, MOUNJARO, NURTEC ODT, REXULTI, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error